The SEO-optimized rewritten version of the provided content is as follows:
«We are consolidating a more innovative, connected, and people-centered healthcare system,» highlighted the Minister of Health, Mónica García, emphasizing that the Cutting-Edge Health PERTE has three strategic lines focused on promoting precision personalized medicine, digital transformation of healthcare, and advanced professional training.
This was stated during the fifth meeting of this project, where it was emphasized that these investments «not only modernize the capacity of the National Health System (NHS), but also prepare it to face future challenges with greater equity, efficiency, and resilience.»
The Minister of Science, Innovation, and Universities, Diana Morant, stated that the Cutting-Edge Health PERTE aims to improve the present and future health of both society and the Spanish economy.
«It is a successful example both in its execution and in its transformative capacity and connection between public and private actors and various administrations, including the autonomous communities,» she added.
It is worth noting that the Cutting-Edge Health PERTE includes 60 different actions coordinated among five ministries, highlighting the launch of Terafront, the first public-private mercantile society in advanced therapies in the country, with an initial investment of 37 million euros of public capital and 38 million private, aimed at accelerating the arrival of cutting-edge therapies through the NHS.
Additionally, progress is being made in the creation of the pioneering National Neurotechnology Center, SPAIN NEUROTECH, to develop technological tools based on the fundamentals of the human brain, a project that will receive 40 million euros from the Recovery, Transformation, and Resilience Plan (PRTR) and an additional 80 million euros from the General State Budget (PGE).
Another achievement of this PERTE is the creation of the world’s first pediatric personal exoskeleton, developed by the company MARSI-Bionics, a spinoff of the Spanish National Research Council (CSIC).
It was also announced during the meeting that Spain will participate in the European Common Interest Project Call in Health (IPCEI-MEDCURE), aiming to enhance research and development of industrial healthcare capabilities in Europe by developing new drugs, better models for identifying and testing therapies, creating new pharmacological substances and innovative vaccines, and establishing innovative production processes towards sustainability in the health value chain.
For this purpose, up to 127 million euros will be allocated to six Spanish companies through the Center for Technological Development and Innovation (CDTI).
Since the last meeting, actions such as the independent Clinical Research call from the Carlos III Health Institute (ISCIII) for 2024 or the TransMissions, a joint call between the CDTI and the State Research Agency (AEI) to combat antimicrobial resistances, have been implemented.